Bogart Wealth LLC Cuts Stake in Amgen Inc. (NASDAQ:AMGN)

Bogart Wealth LLC trimmed its position in Amgen Inc. (NASDAQ:AMGN) by 0.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 20,019 shares of the medical research company’s stock after selling 76 shares during the period. Bogart Wealth LLC’s holdings in Amgen were worth $5,766,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Cullen Frost Bankers Inc. raised its holdings in shares of Amgen by 2.7% during the 4th quarter. Cullen Frost Bankers Inc. now owns 89,834 shares of the medical research company’s stock worth $25,874,000 after acquiring an additional 2,389 shares during the period. EdgeRock Capital LLC purchased a new position in Amgen during the fourth quarter worth about $107,000. Everpar Advisors LLC acquired a new position in Amgen in the 4th quarter valued at about $1,156,000. Gryphon Financial Partners LLC increased its holdings in shares of Amgen by 295.3% during the 4th quarter. Gryphon Financial Partners LLC now owns 3,684 shares of the medical research company’s stock worth $1,021,000 after buying an additional 2,752 shares during the last quarter. Finally, Moss Adams Wealth Advisors LLC acquired a new position in Amgen in the fourth quarter valued at approximately $588,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Trading Up 0.7 %

Shares of Amgen stock traded up $2.27 during trading hours on Thursday, hitting $309.58. The company’s stock had a trading volume of 320,094 shares, compared to its average volume of 2,880,479. The business has a fifty day moving average of $275.65 and a 200 day moving average of $281.74. The company has a market capitalization of $166.07 billion, a PE ratio of 43.90, a P/E/G ratio of 3.00 and a beta of 0.60. Amgen Inc. has a 1-year low of $211.71 and a 1-year high of $329.72. The company has a quick ratio of 0.98, a current ratio of 1.42 and a debt-to-equity ratio of 11.96.

Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, May 2nd. The medical research company reported $3.96 EPS for the quarter, beating the consensus estimate of $3.76 by $0.20. The business had revenue of $7.45 billion for the quarter, compared to the consensus estimate of $7.45 billion. Amgen had a return on equity of 156.21% and a net margin of 12.74%. The company’s revenue was up 22.0% on a year-over-year basis. During the same period last year, the business posted $3.98 EPS. As a group, equities analysts forecast that Amgen Inc. will post 19.46 EPS for the current year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be paid a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a yield of 2.91%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio (DPR) is 128.57%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. The Goldman Sachs Group upped their price target on Amgen from $313.00 to $350.00 and gave the company a “buy” rating in a research note on Wednesday, February 7th. Raymond James assumed coverage on Amgen in a research note on Thursday, March 28th. They issued a “market perform” rating for the company. Royal Bank of Canada decreased their target price on Amgen from $332.00 to $328.00 and set an “outperform” rating on the stock in a research note on Friday, May 3rd. Truist Financial reissued a “buy” rating and issued a $320.00 target price on shares of Amgen in a research report on Friday, April 12th. Finally, TD Cowen lowered their target price on shares of Amgen from $370.00 to $360.00 and set a “buy” rating on the stock in a research report on Wednesday, April 17th. Ten investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $305.65.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 2,117 shares of the company’s stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $313.09, for a total value of $662,811.53. Following the transaction, the senior vice president now directly owns 9,883 shares of the company’s stock, valued at approximately $3,094,268.47. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.69% of the stock is currently owned by company insiders.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.